1
|
Jia F, Chen Y, Xin G, Li L, Liu Z, Xu S, Gao J, Meng H, Shi Y, Ma Y, Li L, Fu J. Shuangshen Ningxin capsule alleviates myocardial ischemia-reperfusion injury in miniature pigs by modulating mitophagy: network pharmacology and experiments in vivo. Chin Med 2023; 18:120. [PMID: 37730607 PMCID: PMC10510173 DOI: 10.1186/s13020-023-00810-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 07/20/2023] [Indexed: 09/22/2023] Open
Abstract
BACKGROUND Myocardial ischemia/reperfusion injury (MI/RI) is involved in a variety of pathological states for which there is no effective treatment exists. Shuangshen Ningxin (SSNX) capsule which is developed by Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine has been demonstrated to alleviate MI/RI, but its mechanism remains to be further elucidated. METHODS The MI/RI miniature pigs model was constructed to assess the pharmacodynamics of SSNX by blocking the proximal blood flow of the left anterior descending branch of the cardiac coronary artery through an interventional balloon. The principal chemical compounds and potential targets of SSNX were screened by HPLC-MS and SwissTargetPrediction. The targets of MI/RI were identified based on Online Mendelian Inheritance in Man (OMIM) and GeneCards. Cytoscape 3.9.0 was applied to construct a protein-protein interaction (PPI) network, and Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using metascape. To further validate the mechanism of SSNX, Molecular docking, Transmission electron microscopy, and Western blot analysis were used to test the effectiveness of targets in related pathways. RESULTS Our results indicated that SSNX significantly improved cardiac function, attenuated myocardial I/R injury. Through network analysis, a total of 15 active components and 201 targets were obtained from SSNX, 75 of which are potential targets for the treatment of MI/RI. KEGG and MCODE analysis showed that SSNX is involved in the mitophagy signaling pathway, and ginsenoside Rg1, ginsenoside Rb1 and ginsenoside Rb2 are key components associated with the mitophagy. Further experimental results proved that SSNX protected mitochondrial structure and function, and significantly reduced the expression of mitophagy-related proteins PTEN-induced putative kinase 1 (PINK1), Parkin, FUN14 domain containing 1 (FUNDC1) and Bcl-2/E1B-19 kDa interacting protein 3 (BNIP3) in MI/RI miniature pigs. CONCLUSION In our study, the integration of network pharmacology and experiments in vivo demonstrated that SSNX interfered with MI/RI by inhibiting mitophagy.
Collapse
Affiliation(s)
- Feifan Jia
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Yuanyuan Chen
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Gaojie Xin
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Lingmei Li
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Zixin Liu
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Sujuan Xu
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Jiaming Gao
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Hongxu Meng
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Yue Shi
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Yanlei Ma
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China
| | - Lei Li
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China.
| | - Jianhua Fu
- National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China.
| |
Collapse
|
2
|
Yan LL, Wei XH, Shi QP, Pan CS, Li KY, Zhang B, Wang XG, Zheng B, Wang MX, Yan L, Huang P, Liu J, Fan JY, Li H, Wang CS, Chen M, Han JY. Cardiotonic Pills® protects from myocardial fibrosis caused by in stent restenosis in miniature pigs. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 106:154405. [PMID: 36067659 DOI: 10.1016/j.phymed.2022.154405] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 07/18/2022] [Accepted: 08/17/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Stent implantation has been increasingly applied for the treatment of obstructive coronary artery disease, which, albeit effective, often harasses patients by in-stent restenosis (ISR). PURPOSE The present study was to explore the role of compound Chinese medicine Cardiotonic Pills® (CP) in attenuating ISR-evoked myocardial injury and fibrosis. STUDY DESIGN Chinese miniature pigs were used to establish ISR model by implanting obsolete degradable stents into coronary arteries. Quantitative coronary angiography (QCA) was performed to confirm the success of the model. METHODS CP was given at 0.2 g/kg daily for 30 days after ISR. On day 30 and 60 after stent implantation, the myocardial infarct and myocardial blood flow (MBF) were assessed. Myocardial histology was evaluated by hematoxylin-eosin and Masson's trichrome staining. The content of ATP, MPO, and the activity of mitochondrial respiratory chain complex Ⅳ were determined by ELISA. Western blot was performed to assess the expression of ATP5D and related signaling proteins, and the mediators of myocardial fibrosis. RESULTS Treatment with CP diminished myocardial infarct size, retained myocardium structure, attenuated myocardial fibrosis, and restored MBF. CP ameliorated energy metabolism disorder, attenuated TGFβ1 up-regulation and reversed its downstream gene expression, such as Smad6 and Smad7, and inhibited the increased expression of MCP-1, PR S19, MMP-2 and MMP-9. CONCLUSION CP effectively protects myocardial structure and function from ISR challenge, possibly by regulating energy metabolism via inactivation of RhoA/ROCK signaling pathway and inhibition of monocyte chemotaxis and TGF β1/Smads signaling pathway.
Collapse
Affiliation(s)
- Lu-Lu Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Xiao-Hong Wei
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Qiu-Ping Shi
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Chun-Shui Pan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Kai-Yin Li
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Bin Zhang
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Xin-Gang Wang
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Bo Zheng
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China
| | - Ming-Xia Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Li Yan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Ping Huang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Jian Liu
- Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Jing-Yu Fan
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Huan Li
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China
| | - Chuan-She Wang
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China
| | - Ming Chen
- Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Cardiology, Peking University First Hospital, XiCheng District, Beijing 100034, China.
| | - Jing-Yan Han
- Tasly Microcirculation Research Center, Peking University Health Science Center, Haidian District, Beijing 100191, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Haidian District, Beijing 100191, China; State Key Laboratory of Core Technology in Innovative Chinese Medicine, Haidian District, Beijing 100191, China; Beijing Laboratory of Integrative Microangiopathy, Haidian District, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Haidian District, Beijing 100191, China.
| |
Collapse
|